Identifying and Managing Patients at Risk for HBV Reactivation

In this CME-certified video module, Leonard H. Calabrese, DO; Robert P. Perrillo, MD, FAASLD; and Andrew D. Zelenetz, MD, PhD, discuss best practices in HBV screening and prophylaxis for patients who will undergo immunosuppressive therapy.
Leonard H. Calabrese, DO
Robert P. Perrillo, MD, FAASLD
Andrew D. Zelenetz, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 18, 2016 Expiration: October 17, 2017

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement strategies to ensure that patients at risk for HBV reactivation are identified and appropriately screened
  • Apply current management guidelines and expert recommendations for the prevention and management of HBV reactivation

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Leonard H. Calabrese, DO

Professor of Medicine
Department of Rheumatology
Cleveland Clinic
Cleveland, Ohio

Leonard H. Calabrese, DO, has disclosed that he has received fees for non-CME/CE services from AbbVie, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Pfizer, and UCB.
Robert P. Perrillo, MD, FAASLD

Senior Investigator
Hepatology Division
Baylor University Medical Center
Adjunct Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Robert P. Perrillo, MD, FAASLD, has disclosed that he has received consulting fees from Dynavax.

Andrew D. Zelenetz, MD, PhD

Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York

Andrew D. Zelenetz, MD, PhD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, and Roche, consulting fees from Adaptive Biotechnology, Amgen, Celgene, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, Janssen, Nanostring Tech, Novartis, Portola Pharmaceuticals, and Takeda, and holds membership with a data monitoring committee with Boehringer Ingelheim.


Megan K. Murphy, PhD

Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Ryan P. Topping, PhD

Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists, rheumatologists, gastroenterologists, hepatologists, infectious disease physicians, and other healthcare professionals involved in the management of patients at risk for HBV reactivation.


The goal of this activity is to improve participants’ competence in identifying patients at risk of HBV reactivation, providing appropriate HBV screening, and implementing preventive therapy as appropriate.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 18, 2016, through October 17, 2017:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary from Roy Fleischmann, MD, on when to select biologic or targeted synthetic DMARD monotherapy for treating rheumatoid arthritis.

Roy Fleischmann, MD Released: June 8, 2018

Despite demonstration of comparable efficacy and safety between biosimilars and their originators, some patients avoid this treatment switch. Here’s my take on steps to assuage unfounded patient fears.

Jonathan Kay, MD Released: February 13, 2018

Watch our recent quiz game on biosimilars in rheumatologic conditions.

Stanley B. Cohen, MD Jonathan Kay, MD Kenneth G. Saag, MD, MSc Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: November 28, 2017 Expiration: November 27, 2018

In this downloadable slideset, Jonathan Kay, MD, explores key concepts including immunogenicity, switching, and interchangeability of biosimilars.

Released: November 21, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an independent educational grant from
Gilead Sciences

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?